Skip to content
Clinical Trials – home
Therapeutic area

Endocrine disorders – page 17

  • 497 clinical trials
  • 183 recruiting
  • 211 conditions
  • 25 countries

Conditions in this area

211 conditions with trials, the busiest first

Clinical trials in Endocrine disorders

497 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

497 clinical trials

Cushing's syndrome

Not yet recruiting

Efficacy and safety of osilodrostat with drug combination in patients with hypertension caused by Cushing's syndrome

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Recordati AG

Monogenic diabetes

Not yet recruiting

Effect of semaglutide added to sulfonylurea on blood sugar in adults with HNF1A‑MODY and HNF4A‑MODY

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Steno Diabetes Center Copenhagen

Adrenocortical carcinoma

Not yet recruiting

Cisplatin with drug combination in hyperthermic intraperitoneal chemotherapy for stage II‑III adrenocortical carcinoma patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Neuroendocrine carcinoma

Not yet recruiting

Phase II Study of BI 764532 Added to Platinum Chemotherapy in Adults with Advanced Large‑Cell Neuroendocrine Lung Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Igg-Like T Cell Engager Binding To Dll3 And Cd3
  • Sponsor:Technische Universitaet Dresden

Adrenal insufficiency

Not yet recruiting

Oral bioavailability and tolerability of hydrocortisone tablets vs hydrocortisone sodium phosphate orodispersible films in children and adolescents with adrenal insufficiency

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Hydrocortisone
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Acromegaly

Not yet recruiting

Short-Acting Pasireotide Test to Predict Treatment Response in Patients with Acromegaly

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pasireotide
  • Sponsor:Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol

Overweight+1

Not yet recruiting

Effect of bupropion hydrochloride and mushroom supplement on body weight in overweight adults: a 52‑week randomized trial

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Bupropion Hydrochloride
  • Sponsor:Uppsala University

Glucose tolerance impaired

Not yet recruiting

Effect of Metformin Hydrochloride on Inflammation and Aging Biomarkers in Pre‑diabetic Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · Healthy volunteers
  • Substances:Metformin Hydrochloride

Paraganglion neoplasm+1

Not yet recruiting

Evaluation of D-Glucose-13C6 Test for Detecting SDHx Mutations in Patients with Pheochromocytoma or Paraganglioma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Assistance Publique Hopitaux De Paris

Type 1 diabetes mellitus

Not yet recruiting

Effect of Verapamil Hydrochloride on Beta Cell Function in Children and Adults Aged 7‑45 with Stage 1 or Stage 2 Type 1 Diabetes (48‑Week Study)

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Verapamil Hydrochloride
  • Sponsor:Assistance Publique Hopitaux De Paris

Neuroblastoma

Not yet recruiting

Feasibility Study of AloCelyvir and Autologous Tumor‑Infiltrating T Lymphocytes in Children and Young Adults with High‑Risk Relapsed/Refractory Neuroblastoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Allogenic Bone Marrow-Derived Mesenchymal Stem Cells Transduced With Icovir-5, Ex Vivo Expanded
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa

Adrenogenital syndrome

Not yet recruiting

Study of Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia to Reduce Androgen Levels

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Crinecerfont
  • Sponsor:Neurocrine Biosciences Inc.

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.